Xinhua Medical disclosed its performance in violation of regulations

2023-08-23 00:09:35

On April 12, Shandong Xinhua Medical Devices Co., Ltd. (hereinafter referred to as “Xinhua Medical”) issued a notice stating that due to failure to release the performance forecast in time before January 31, the relevant regulations were violated. China Securities Regulatory Commission Shandong Regulatory Authority (hereinafter referred to as "CSRC Shandong Regulatory Authority") decided to take regulatory measures for issuing warning letters to the company, and decided to take measures to supervise and talk to the company's chairman, general manager, secretary of the board of directors and financial controller.

On April 5, Xinhua Medical released the 2016 Annual Results Announcement. According to the preliminary calculation of the company's 2016 financial data, Xinhua Medical expects the net profit attributable to shareholders of listed companies from January to December 2016 to decrease by 75 compared with the same period of the previous year. %-95%, the specific financial data will be disclosed in detail in the company's 2016 annual report.

Xinhua Medical's fundraising scale has shrunk frequently: the total amount has dropped to no more than 1.947 billion

According to the “Shanghai Stock Exchange Listing Rules (2014 Revision)” 11.3.1, if the listed company’s estimated annual operating profit increased or decreased by more than 50% compared with the same period of the previous year, it should be after the end of the fiscal year. Performance announcements are made within one month. The Shandong Regulatory Bureau of the China Securities Regulatory Commission believes that Xinhua Medical failed to issue a performance forecast in time before January 31, 2017, in violation of the relevant provisions of Article 25 of the Measures for the Administration of Information Disclosure of Listed Companies. According to the provisions of Article 59 of the Measures for the Administration of Information Disclosure of Listed Companies, the Shandong Regulatory Bureau of the China Securities Regulatory Commission decided to adopt a supervisory measure for issuing warning letters to Xinhua Medical.

Body care products

Body building products : Body care products, 4-Aminobenzamidine Dihydrochloride,Bulk Fluorogesterone Acetate Powder,Bulk Fluocinolone Acetonide Powder,Clomiphene Citrate Powder,


Now we have 3 GMP standard workshop, Meanwhile, the factory is equipped with the researching and quality inspection centre, with strong technology research and development strength. We also have 3 salesdepartments over 30 people and sell our products all over the world.


Xi'an Henrikang Biotech Co., Ltd., has a high-quality talent team and well-equipped quality control laboratory. In the Skin Whitening production enterprises far ahead of other enterprises. Sweeteners we are also a high-quality supplier, absolutely reliable quality, absolutely competitive price. The factory has a RESEARCH and development and quality testing center, with strong technical research and development strength. Preservatives also has 3 sales departments, more than 30 people, and our products are sold all over the world.Nutrition Supplements sales in foreign countries our company has a long-term stable market and partners in Sex Enhancement Powder, We are very professional suppliers, looking forward to cooperating with you, welcome to consult us.

Body care products, 4-Aminobenzamidine Dihydrochloride,Bulk Fluorogesterone Acetate Powder,Bulk Fluocinolone Acetonide Powder,Clomiphene Citrate Powder

Xi'an Henrikang Biotech Co.,Ltd , https://www.henruikangbio.com